VAERS_ID,RECVDATE,STATE,AGE_YRS,CAGE_YR,CAGE_MO,SEX,RPT_DATE,SYMPTOM_TEXT,DIED,DATEDIED,L_THREAT,ER_VISIT,HOSPITAL,HOSPDAYS,X_STAY,DISABLE,RECOVD,VAX_DATE,ONSET_DATE,NUMDAYS,LAB_DATA,V_ADMINBY,V_FUNDBY,OTHER_MEDS,CUR_ILL,HISTORY,PRIOR_VAX,SPLTTYPE,FORM_VERS,TODAYS_DATE,BIRTH_DEFECT,OFC_VISIT,ER_ED_VISIT,ALLERGIES
874013,6/22/2020,FR,5,,,U,,"Arthus reaction; redness at the injection site; swelling at the injection site; Initial information received on 16-Jun-2020 regarding an unsolicited valid serious case received from a physician (medical doctor) via medical representative via email.  This case involves a five year old patient (gender not reported) who experienced redness at the injection site (vaccination site erythema), swelling at the injection site (vaccination site swelling) and was diagnosed with Arthus Reaction (Type III Immune Complex Mediated Reaction), when received INFLUENZA QUADRIVAL A-B VACCINE [FLUQUADRI].  The patient's medical history, past medical treatments, vaccinations, concomitant medications and family history were not provided.  On 13-Jun-2020, the patient received a 0.5 ml dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot number and Expiry date not reported) via an intramuscular route in the left deltoid for prophylactic vaccination.  On 14-Jun-2020, the patient developed redness at the injection site (vaccination site erythema), swelling at the injection site (vaccination site swelling) and was diagnosed with Arthus Reaction (Type III Immune Complex Mediated Reaction) one  day following the administration of INFLUENZA QUADRIVAL A-B VACCINE. These  events were assessed as medically significant.  No laboratory data was provided.  Final diagnosis was Type III immune complex mediated reaction.  The patient was prescribed anti-allergic medication as corrective treatment.  At the time of this report, patient was recovering from all the events.  There will be no information available on the lot number for this case.; Sender's Comments: This case involves a five year old patient who experienced vaccination site erythema, vaccination site swelling and was diagnosed with Type III immune complex mediated reaction one day after vaccination with FLUQUADRI. The time to onset was compatible. However, patient's medical condition at time of vaccination and lab test ruling out alternate etiologies were not reported. Based upon the reported information the role of the suspect vaccine cannot be assessed.",,,,,,,,,N,6/13/2020,6/14/2020,1,,OTH,,,,,,THSA2020SA157011,2,6/22/2020,,,,
875102,7/6/2020,FR,,,,M,,"acute kidney injury; Renal impairment; diabetes mellitus; renal cyst; lipase increased; lymphocyte count decreased; Neutrophil count increased; red blood cell count decreased; blood alkaline phosphatase increased; blood chloride increased; blood gases abnormal; blood urea increased; Glomerular filtration rate decreased; haematocrit decreased; haemoglobin decreased; Tubulointerstitial nephritis; Nephritis allergic; Renal ischaemia; Dyspnoea exertional; Fluid overload; Rhinitis; oedema peripheral; Viral infection; acidosis; Blood creatinine increased; blood bicarbonate decreased; heart rate increased; hypersensitivity; influenza like illness; lethargy; chest discomfort; dehydration; blood potassium increased; Urinary tract infection; Information has been received from the regulatory authority (AU-TGA-0000461447) on 22-JUN-2020.   This is a spontaneous case initially received from the pharmacist on 22-MAR-2019, concerning an adult male patient (68-year-old at the time of report). On 18-MAY-2009, the patient was administered Fluvax vaccine. The patient's historical condition included bladder cancer (reported as bladder CA). The patient's current conditions included hypertension (reported as medical history), chronic renal impairment (CRI) which was known to renal physician, decreased estimated glomerular filtration rate (EGFR) (30-40) and baseline creatinine level of 200 (reported as medical history) and neo-bladder. The patient's current procedure included self-catheterization. The patient's concomitant medications included candesartan (reported as candesarten) and gliclazide. On 17-MAY-2013, the patient was administered Fluvax (TIV) (influenza vaccine, dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication. On an unspecified date, after vaccination, the patient experienced flare up of renal impairment. On 27-MAY-2015, the patient was administered non-company suspect vaccines- Fluarix (dose, route of administration, anatomical location, batch number and expiry date: not reported) and Pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) 23 (dose, route of administration, anatomical location, batch number and expiry date: not reported) for unknown indications. On an unspecified date in July 2015, September 2015 and April 2016, the patient experienced recurrent episodes of urinary tract infection (UTI) respectively. The patient had chronic renal impairment due to recurrent episodes of UTI. On 02-MAY-2016, the patient was administered non-company suspect vaccine- influenza virus split virion 4v vaccine inactivated (FLUARIX TETRA) (dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication. On 10-Oct-2016, the patient was administered non-company suspect vaccine diphtheria toxoid, pertussis acellular 3-component vaccine, tetanus toxoid (BOOSTRIX), (dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication. On 06-APR-2017, the patient was administered non-company suspect vaccine Zoster vaccine live (ZOSTAVAX), (dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication. On 22-MAY-2017, the patient was administered non-company suspect vaccine influenza virus split virion 4v vaccine inactivated (FLUARIX TETRA) (dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication. On an unspecified date in MAY-2017, the patient experienced recurrent episode of urinary tract infection (UTI). On 08-JUN-2018, at the age of 68 years, the patient was administered non-company suspect vaccine Fluzone (dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication.  On an unspecified date in 2018, the patient experienced flu like symptoms for 3/52 (as reported). On an unspecified date in June 2018, the patient experienced allergic type interstitial nephritis and was treated with prednisolone (wearing dose plan). The patient also experienced chronic glomerular ischemia. On an unspecified date in 2018, the patient experienced acute renal failure with the symptoms of worsening lethargy and shortness of breath on exertion. The patient also developed mild coryzal symptoms and since then, had a gradual worsening of symptoms (unspecified). The patient had no fevers and pain but had chest tightness. The patient was seen by the general practitioner (GP) and underwent blood test which demonstrated acute on chronic renal impairment and creatinine level was 673 (blood creatinine increased). The patient was alert, oriented and afebrile. The patient's other examinations included increased heart rate: 108, respiratory rate (RR): 18 at rest, tachypnoea with exertion, oxygen saturation rate: 98 percent (normal) (reported as SATS RA). The patient's chest examination included bilateral air entry S1 and S2, abdomen was soft and non-tender and mild pitting oedema in the legs. The patient's electrocardiogram (ECG) included sinus rhythm (SR), mild tenting of T waves and there was no previous test to compare with. The patient's blood examination included PH of 7.4 (normal), creatinine: 730 (increased), bicarbonate levels 6 (decreased) and potassium levels: 5.7 (increased). It was noted that, the patient had acute on chronic renal failure with acidosis and mild fluid overload and needed hemofiltration. The investigational plan included CT scan of renal (for imaging) and ICU referral for hemofiltration. On 21-JUL-2018 at 00: 05 hours, the patient was admitted to the hospital and was transferred to ICU. The suspected etiology of acute renal impairment included viral illness, dehydration and patient was on Atacand (candesartan). The patient had moderate allergic reactions. The patient had no documented reactions to morphine and reactions to Triprim (trimethoprim) was unknown.  On 21-JUL-2018 at 1:53 hours, the laboratory investigations in discharge report included, haemoglobin: 104 g/L (low), white cell count: 11.4x 10E9/L (normal), platelet count: 287x10E9/L (normal), red blood cell count: 3.34x10E12/L (low), haematocrit: 0.31 L/L (low), mean corpuscular volume: 92 femtolitre (FL) (normal), mean corpuscular haemoglobin: 31.0 per gram (pg) (normal), mean cell haemoglobin concentration: 338 g/L (normal), neutrophils absolute: 9.7x10E9/ L (high), lymphocyte absolute: 0.7x10E9/ L (low), monocytes absolute: 0.9x10E9/ L (normal), eosinophils absolute: 0.1x10E9/L (normal), basophils absolute: 0.0x10E9/L (normal). The patient's haematology report (FBE) included sodium level: 139 mmol/L (normal), potassium level: 5.7 mmol/ L (high), chloride level: 111 mmol/ L (high), bicarbonate level: 5 mmol/ L (low), urea level: 47.0 mmol/ L (high), creatinine level: 742 micromol/ L (high), eGFR: 6 (low), total bilirubin: 2 micromol/ L (normal), alanine aminotransferase: 20 units/L (normal), gamma glutamyl transferase: 20 units/ L (normal), alkaline phosphatase: 204 units/L (high), protein total: 71 g/L (normal), albumin level: 39 g/L (normal), globulin level: 32 g/L (normal), lipase level: 173 units/ L (high). The patient's general chemistry report included blood gas fraction of inspired oxygen (FiO2): 21 percent (low). The sample type venous results included blood gas pH: 7.04 (low), blood gas partial pressure of oxygen (pO2): 42 mmHg (low), blood gas partial pressure of carbon-di-oxide (pCO2): 24 mmHg (low), blood gas bicarbonate: 6 mmol/L (low), blood gas O2 saturation: 70 percent (low), blood gas sodium: 138 mmol/ L (normal), blood gas potassium: 5.54 mmol/L (normal), blood gas chloride: 117 mmol/L (high), blood gas calcium ionized: 1.11 mmol/L (low), blood gas total haemoglobin: 107 g/L (low), blood gas oxyhaemoglobin: 69.3 percent (low), blood gas carboxyhaemoglobin: 0.5 percent (normal), blood gas methaemoglobin: 1.1 percent (normal), blood gas reduced haemoglobin: 29.1 percent (high), blood gas total bilirubin: 9 micromol/L (normal), blood gas blood glucose: 6.9 mmol/L (normal), blood gas lactate: 0.6 mmol/L (normal), blood gas base excess: 23.2 mmol/L (low), blood gas temperature: 37.0 Celsius (normal).   On the same day, the patient was discharged from the hospital. The patient's discharged medications were not provided. On 12-OCT-2018, the patient developed right renal cyst. On 26-OCT-2018, the patient experienced diabetes. It was reported that on an unspecified date, the patient died (reported as deceased), which was unrelated to allergic reactions. The cause of death was unknown and autopsy reports was not provided. The outcome of the event interstitial nephritis was resolved, and outcome of other events was not reported. The reporter assessed the case as serious (death). This case (201902696) was linked to the case: 201902695 (same patient). Follow-up information received from pharmacist on 25-MAR-2019: Added date of birth and the age group of the patient in tab. The reporter also confirmed the vaccination date of the Fluzone vaccine (08-JUN-2018) and experienced flu like symptoms for 3/52 (as reported). It was reported that the patient was hospitalized on 21-JUL-2018 and received prednisolone as treatment for allergic type interstitial nephritis. The narrative was amended accordingly. Non-significant follow up retrieved from regulatory authority (regulatory authority Reference number: AU-TGA-0000461447), reported to regulatory authority by pharmacist on 03-APR-2019: The regulatory authority reference number AU-TGA-0000461447 was added in the additional information tab. No changes were made in narrative. Follow up received from the pharmacist on 06-MAY-2019: The patient's age at vaccination (63 years) were added in the patient tab. The patient's current condition ‘renal disease' was deleted in the patient tab. The patient's historical conditions (UTI, nephritis) and current condition (diabetes) were deleted from the patient tab and added as events in the event tab. The patient's current conditions (hypertension, chronic renal impairment (CRI), decreased estimated glomerular filtration rate (EGFR), baseline creatinine level of 200 and neo-bladder) were added in the patient tab. The patient's current condition bladder cancer was coded as historical condition in the patient tab. The patient's historical vaccine influenza virus split virion 4v vaccine inactivated (FLUARIX TETRA) was deleted and the historical vaccine Afluria Quad was recoded to Fluvax in the patient tab. The patient's current procedure (self-catherterization) was added in the patient tab. The patient's lab investigations were added in the patient tab. patient's suspect vaccine Afluria Quadivalent was recoded to Fluax (TIV) in the product tab and listedness was done accordingly in the event assessment tab. The patient's co-suspect vaccines (Pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) 23, Zoster vaccine live (ZOSTAVAX), Fluarix, influenza virus split virion 4v vaccine inactivated (FLUARIX TETRA), diphtheria toxoid, pertussis acellular 3-component vaccine, tetanus toxoid (BOOSTRIX), and FLuzone) were added in the product tab. The patient's treatment medication (prednisolone) was added in the product tab. The patient's events (death, acute renal failure, nephritis interstitial, nephritis allergic, diabetes, renal ischemia, acidosis, fluid overload, recurrent UTI, flu like symptoms, viral infection, chest tightness, coryzal symptoms, dehydration, renal cyst, blood bicarbonate decreased, heart rate increased, potassium increased, hemoglobin decreased, hematocrit decreased, red blood cell count low, absolute neutrophil count increased, absolute lymphocyte count decreased, blood chloride increased, alkaline phosphatase increased, lipase increased, blood gases abnormal, allergic reaction, lethargy, exertional dyspnoea, pitting leg oedema, urea blood level increased, creatinine high and estimated glomerular filtration rate decreased) were added in the event tab. The narrative was amended accordingly.",,,,,,,,,Y,5/27/2015,7/1/2015,35,Test Date: 2018; Test Name: oxygen saturation; Test Result:  98 %,UNK,,candesartan; gliclazide,,,,AU0095075132006AUS009140,2,7/2/2020,,,,
876031,7/14/2020,FR,46,46,,M,,"the patient had a significant weight loss; he had a reaction of a malaise as if it were a ‘hangover'; dizziness; a lot of allergic process; spots on his body; nausea; feeling of weakness as if it were hangover; tiredness; shortness of breath; skin lesions (typical of an allergic process); a lot of pain; a lot of malaise/ unwell; feeling that he would die; reddish rash; discomfort; This case was reported by a nurse via sales rep and described the occurrence of skin lesion in a 46-year-old male patient who received HAB (Twinrix adult) (batch number AHABB382AN, expiry date unknown) for prophylaxis.   Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number AC37B313AB, expiry date unknown) for prophylaxis and Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2019-2020 season) (batch number UJ373AB ?, expiry date unknown) for prophylaxis.   On 16th May 2020, the patient received the 1st dose of Twinrix adult, Boostrix and Influenza vaccine Quadrivalent 2019-2020 season. On an unknown date, less than a month after receiving Twinrix adult, Boostrix and Influenza vaccine Quadrivalent 2019-2020 season, the patient experienced skin lesion, pain, malaise, feeling abnormal and red rash. On an unknown date, the outcome of the skin lesion, pain, malaise, feeling abnormal and red rash were recovered/resolved.   It was unknown if the reporter considered the skin lesion, pain, malaise, feeling abnormal and red rash to be related to Twinrix adult, Boostrix and Influenza vaccine Quadrivalent 2019-2020 season.  Additional details were reported as follows: The age at vaccination was not reported. The patient received vaccines Twinrix, flu vaccine tetravalent and Boosterix on the same day. The patient informed that the vaccine (Hepatitis A and B), caused a very strong reaction, skin lesions (typical of an allergic process), a lot of pain, a lot of malaise, a feeling that he would die. However, the patient said that on the day of reporting he was better. The reporter also sent a photo of what appears to be the patient's forearm with reddish rashes.  The patient's leg also appears in the photo, in addition to the forearm but it was normal.  It was not mentioned in the report whether the picture was taken after the first or second administration. No other information was provided. The reporter consented to follow up. For tolerance of 2nd dose to Twinrix refer case, BR2020AMR110358.    Follow-up information received from nurse on 30th June 2020: The patient's sister contacted the clinic on the date of reporting and said that the patient was unwell and they are waiting for a position. As per followup of 1st July 2020, the first administration of the vaccine was with coadministration of the vaccines DTPa and tetravalent flu vaccine, however in the return for administration of the second dose of Twinrix, no vaccine was co-administered and the patient had the same reactions. The reporter reported that one day before date of reporting a patient's family member contacted her informing that the patient had a significant weight loss, that he had a feeling of discomfort and dizziness, as if it were a hangover and that he was demanding positioning from the clinic. Less than a month after receiving the vaccine the patient had weightloss, discomfort, dizziness and hangover. No other information was provided. It was unknown if the reporter considered the weight loss, hangover, dizziness and discomfort to be related to Twinrix adult, Boostrix and tetravalent flu vaccine.   Follow-up information received from nurse on 7th July 2020: The patient's demographic details were updated. The suspect Influenza vaccine Quadrivalent 2019-2020 season, updated to Influenza vaccine Quadrivalent 2020-2021 season. The reporter stated that last week from the reporting date, a report was made informing that the patient was having a lot of allergic process, spots on his body, dizziness, nausea, feeling of weakness as if it were hangover.  The patient's relative made a new contact and informed that last sunday from the reporting date, patient was admitted at the hospital and underwent several tests, such as blood count and tomography. The patient also attended several medical appointments, upon tomography, a doctor said that the reaction was due to the vaccine.  The reporter believed that the patient had some other disease and wanted to blame the vaccine, as she was not the one who attended the relative, she informed a new email for us to speak with the person in charge. The reporter consented to follow up, if any other contact attempt was needed. All information available were obtained. The reporter confirmed that the DTPA-R and Tetravalente flu vaccines were administered on 16th May 2020, together with the 1st dose of the Hepatitis A+B vaccine. The reporter stated that after the 1st dose, patient had already reported a malaise and allergic process. According to patient and his family, events increased: weight loss, weakness, tiredness, shortness of breath, among other symptoms. The events had not resolved till the time of reporting. The symptoms started on the 1st day after the 1st dose was administered. The reporter was precisely in doubt about event associated with the use of the medication or not. The patient's family was very worried, investigated symptoms, with medical help. It was unknown if patient used any concomitant medication or had any relevant medical history. The reporter considered the weight loss, hangover, dizziness, allergy, skin staining, nausea, weakness, tiredness, shortness of breath, skin lesion, pain, malaise, feeling abnormal, red rash and discomfort to be related to Twinrix adult, Boostrix and Influenza vaccine Quadrivalent 2020-2021 season. The patient was under medical care at the time of reporting because his health condition had became much worse.  The reporter asked for urgency in this return, because the clinic (vaccination clinic) did not know what to do anymore. No other information was provided.; Sender's Comments:  BR-GLAXOSMITHKLINE-BR2020AMR110358:Same reporter",,,,,Y,,,,N,5/16/2020,5/17/2020,1,"Test Date: 20200705; Test Name: blood count; Result Unstructured Data: (Test Result:result value not provided,Unit:unknown); Test Date: 20200705; Test Name: lab test; Result Unstructured Data: (Test Result:Tomography result not provided,Unit:unknown)",UNK,,,,,,BRGLAXOSMITHKLINEBR2020AM,2,7/14/2020,,Y,,
